FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
ST. LOUIS, Nov. 02, 2017 -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 third quarter ended September 30, 2017 on Thursday, November 9, 2017 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments.
What: Stereotaxis third quarter 2017 financial results conference call
When: Thursday, November 9th at 10:00 a.m. Eastern Time (7:00 a.m. PT)
Dial In Number: To access the live call, dial 800-776-0487 (US and Canada) or 719-325-4880 (International) and give the participant pass code 8418426.
Webcast: To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at www.stereotaxis.com
Call Replay: A phone replay of the call will be available for one week beginning approximately two hours following the end of the call through Thursday, November 16, 2017. To access the replay dial-in information, please click here.
About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
Company Contacts:
David L. Fischel
Chairman and Acting Chief Executive Officer
Martin C. Stammer
Chief Financial Officer
314-678-6100
[email protected]
